[ad_1]
(Boursier.com) — The operating income ofAB Science are exclusively made up of turnover linked to the exploitation of a medicinal product in veterinary medicine. As of June 30, 2024, turnover is increasing and amounts to €560 thousand compared to €448 thousand as of June 30, 2023.
Operating expenses decreased by -55.45% between the 1st half of 2023 and the 1st half of 2024. The operating deficit decreased by 5.27 ME, i.e. a drop of -59.5%, from -8.85 ME to 1st half of 2023 at -3.58 ME in the 1st half of 2024.
The financial result corresponds to a loss of -887 kE for the 1st half of 2024 (-1.57 ME in the 1st half of 2023).
The net loss as of June 30, 2024 amounts to -4.47 ME (-10.41 ME as of June 30, 2023), a decrease of -57.07%.

The total cash and current financial assets of AB Science amounted to 9.13 ME as of June 30 (6.07 ME as of December 31, 2023). As of June 30, 2024, the company’s equity is negative and amounts to -22.22 ME.
Outlook
In 2024, AB Science will continue the continued development of its two development platforms, masitinib and the microtubule destabilizing agents (MDA) platform.
For masitinib, AB Science remains focused on the licensing search procedure. This license search is justified given the additional investments required to complete the confirmatory phase 3 clinical program.
AB Science specifies that the duration of this license search is not predictable and that the realization of a license depends on a certain number of factors and is not guaranteed. However, the milestones reached at this stage are essential factors that contribute to the feasibility of this strategy.
For AB8939, the recent fundraising of 5 ME will support the phase 2 clinical development of this molecule.
Finally, the company will continue to invest in drug discovery activities in order to supply its portfolio of molecules.
©2024 Boursier.com
[ad_2]
Source link -87